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ABSTRACT
IL-2 is a pleiotropic cytokine that plays an essential role in the survival, expansion, and function of CD8
T cells, regulatory T cells (Tregs), and natural killer (NK) cells. Previous studies showed that binding IL-2
with an anti-IL-2 monoclonal antibody (mAb) with a particular specificity could block its interaction with
IL-2Rα, which is mainly expressed on Tregs. This selectivity can enhance the anti-tumor effects of IL-2 by
activating CD8 T and NK cells, while disfavoring Treg stimulation. Based on this, we newly developed
a series of anti-human IL-2 (hIL-2) mAbs (TCB1-3) that selectively stimulate CD8 T and NK cells without
overtly activating Tregs. Among them, the hIL-2/TCB2 complex (hIL-2/TCB2c) exerted the best efficacy by
inducing a prodigious expansion of host memory phenotype (MP) CD8 T (60-fold) and NK cells (18-fold)
with less efficient Treg proliferation (5-fold). As a result, there was an average eightfold increase in the
ratio of MP CD8 to Tregs. Accordingly, hIL-2/TCB2c strongly inhibited the growth of B16F10, MC38, and
CT26 tumors. More remarkably, hIL-2/TCB2c showed synergy with checkpoint inhibitors such as anti-
CTLA-4 or PD1 antibodies, and resulted in almost complete regression of implanted tumors and
resistance to secondary tumor challenge. For direct clinical use, we generated a humanized form of
TCB2 that had equal immunostimulatory and anti-tumor efficacy as a murine one. Collectively, these
results show that TCB2 can provide a potent immunotherapeutic modality either alone or together with
checkpoint inhibitors in cancer patients.
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Introduction
IL-2 receptor (IL-2R) is widely expressed on the surface of
various lymphoid cells, including CD8 T cells, Foxp3+ regu-
latory T (Treg) cells, and natural killer (NK) cells.1 It is
composed of IL-2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ
(γc, CD132) subunits, and exists as either αβγ heterotrimeric
or βγ heterodimeric complexes.2–4 When CD25 binds to IL-2,
it induces a conformational change in IL-2 and increases its
binding affinity to the IL-2Rβ and IL-2Rγ to form a tetrameric
IL-2/IL-2 receptor complex.5 In this way, Tregs have 10 to
100-fold higher binding affinity to IL-2. At the steady state,
survival of Tregs is dependent on IL-2 and, upon inflamma-
tion, Tregs can preferentially bind to soluble IL-2, thereby
inhibiting conventional T cell activation.6
IL-2 highly stimulates CD8 T and NK cells that can boost
anti-tumor immunity, and recombinant human IL-2 (hIL-2),
aldesleukin, has been approved for clinical use by the FDA in
1996 and 1992 for the treatment of metastatic melanoma and
renal cell carcinoma, respectively.7 Approximately 10% of
patients showed a durable response, but serious toxic side
effects were observed due to the expression of the heterotri-
meric IL-2 receptor in lung endothelial cells, which caused
fatal vascular leak syndrome.8–10 Also, IL-2 administration
induced a robust Treg expansion that suppressed the anti-
tumor activity of CD8 T and NK cells. Moreover, unmodified
hIL-2 had an extremely short half-life in vivo, further limiting
its usage.
One way to circumvent the pitfalls of aldesleukin is to modify
IL-2 in a way to extend its in vivo lifespan and preferentially direct
its effects toCD8T andNKcells, but not Tregs or endothelial cells.
In 2006, Boyman and colleagues reported that when a cytokine is
complexed with its antibody, it dramatically increases its in vivo
half-life and efficacy.2 Depending on the structure of the complex,
it could also be selective for different forms of receptors. For
example, anti-IL-2 antibodies such as S4B6 (anti-mouse) and
MAB602 (anti-human) can preferentially stimulate CD8 T or
NK cells, while JES6-1 (anti-mouse) or 5344 (anti-human) favor
the proliferation of Tregs. The recently developed anti-hIL-2
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antibody, Nara1, can preferentially stimulate the dimeric IL-2
receptor when complexed with hIL-2.11 Structurally, Nara1 binds
near the CD25 binding site of IL-2 and abolishes its binding to IL-
2, thereby disfavoring Treg activation.
In this report, we generated anti-hIL-2 antibodies and
screened clones that could preferentially work on the dimeric
IL-2 receptor by blocking the CD25 binding motif. We
selected three clones, named TCB1–3, and found that TCB2
has a unique CDR sequence compared to TCB1, TCB3, and
Nara1. The hIL-2/TCB2 complex (hIL-2/TCB2c) had excep-
tional in vivo efficacy in stimulating CD8 T and NK cells, and
could inhibit the growth and spread of various tumors such as
MC38, CT26, and B16F10. When hIL-2/TCB2c was combined
with checkpoint inhibitors such as anti-PD1 or CTLA4 anti-
bodies, tumors were almost completely regressed in mice.
Finally, we generated a humanized form of TCB2 that we
confirmed to have equal immunostimulatory and anti-tumor
effects as a murine one. Collectively, we showed that TCB2 is
a new anti-hIL-2 monoclonal antibody (mAb) that has poten-
tial therapeutic effects in human cancer patients.
Material and methods
Mice
BALB/c, C57BL/6 (B6), Thy1.1 Foxp3-eGFP, mice were
maintained at POSTECH Biotech Centre (Korea) under
specific pathogen-free condition. For the experiments
with anti-tumor effect, B6 or BALB/c mice were purchased
from OrientBio (Korea). Unless it is specified, all mice
with 6–10 weeks old were used for the experiments
according to the protocols approved by the Animal
Experimental and Ethic Committee at the Institute for
Basic Science (Korea).
Flow cytometry
Single-cell suspensions were prepared from indicated organs
and FACS stained in PBS buffer containing 2% FBS and 0.05%
sodium azide. For intracellular staining, single-cell suspensions
were surface stained, fixed, and permeabilized with eBioscience
Foxp3 staining buffer set. Following antibodies from BD
bioscience, BioLegend or ThermoFisher were used for surface
or intracellular staining; CD3 (145-2C11), CD4 (GK1.5 or
RM4–5), CD8α (53–6.7), CD25 (PC61), CD44 (IM7), CD62L
(MEL-14), CD69 (H1.2F3), CD90.1 (HIS51 or OX-7), CD122
(TM-β1), CD132 (TUGm2), TCRβ (H57-597), NK1.1 (PK136),
Granzyme B (GB11), Foxp3 (MF-14), IFN-γ (XMG1.2), NKp46
(29A1.4), CD11b (M1/70), CD27 (LG.7F9), T-bet (4B1D) and
pSTAT5 (47/Stat5(pY694)). For pSTAT5 staining, B6 mice
were intravenously injected with PBS, hIL-2 (1 µg), hIL-2/
5344 (1 µg/10 µg), hIL-2/MAB602 (1 µg/10 µg) or hIL-2/
TCB2 (1 µg/10 µg) complexes. After RBC lysis using ACK
buffer, blood mononuclear cells were fixed with 1.6% PFA
(EMS, 25°C) and methanol (DUKSAN, – 20°C) for 10 min,
respectively, and stained with surface and intracellular markers
for 1 h at room temperature.12 Samples were analyzed using
a LSR II or FACSCanto II (BD Biosciences) and analyzed with
FlowJo software (Tree Star).
Generation of anti-hIL-2 mAb producing hybridoma
Immunization of mice and fusion of splenocytes with SP2/0
myeloma cell line (ATCC) was performed as described
previously.13 In brief, splenocytes from BALB/c mice that were
immunized with 20–30 µg of human IL-2 (hIL-2, Prospec)
intraperitoneally for 3–4 times over several weeks were fused
with SP2/0 myeloma cell line. Clones were grown in RPMI1640
(Welgene) supplemented with 10% fetal bovine serum (FBS,
Atlas Biological), penicillin-streptomycin (Welgene) and hypox-
anthine-aminopterin-thymidine (Gibco). Once colonies of
hybridoma were visible, the culture supernatants were subjected
to ELISA against hIL-2. The positive clones were sub-cloned
through serial dilution to ensure that the cell line is the progeny
of a single clone.
Purification of anti-hIL-2 mAbs
Culture supernatant from hybridoma were concentrated by
adding 50/45 (v/v) of saturated ammonium sulfate
(DAEJUNG) and kept at 4°c for overnight. Precipitates were
reconstituted with PBS and then dialyzed for three times
against 0.1 M sodium acetate (pH 5.0). Antibodies were pur-
ified using protein G resin (GE Healthcare) according to the
protocol from the manufacturer.
Biotinylation of antibodies
Monoclonal antibodies were biotinylated using EZ-Link™
NHS-LC-LC-Biotin (Thermofisher) according to the protocol
from manufacturer.
Enzyme-linked immunosorbent assay (ELISA)
To check antibody cross-reactivity, mouse or human IL-2
(mIL-2, Peprotech, and hIL-2, Prospec) were plate coated
(5µg/ml) overnight and serially diluted anti-hIL-2 (MAB602,
R&D systems) or anti-mIL-2 (JES6-1 and S4B6, BioXcell) was
applied for 30 min. After washing, anti-mouse or rat IgG-HRP
(Southern Biotech) was applied for 15 min, then added tetra-
methylbenzidine (TMB, Surmodics). The reaction was stopped
by adding 2NH2SO4 and OD450 was measured using microplate
photometer. To check binding site competition of MAB602 and
TCBs on hIL-2, anti-hIL-2 (clone 5344, BD biosciences)
that does not share binding epitope with MAB602 was coated
(5µg/ml) overnight. Then, hIL-2 (10ng/ml) was applied for 30
min and serial dilutions of TCBs were applied for 30 min after
washing. Biotinylated MAB602 (0.1µg/ml) was added without
washing and incubated for 30 min. After washing, Streptavidin-
HRP (Thermo Scientific) was added for 15 min followed by
TMB reaction. For sandwich ELISA against hIL-2, monoclonal
antibodies against hIL-2 were plate coated (2µg/ml) overnight
and hIL-2 (10ng/ml) was applied for 30 min followed by bioti-
nylated detection antibodies (0.1µg/ml) for 30 min.
hIL-2 complex preparation
hIL-2 (500 ~ 1000 µg/ml, Genescript) and anti-hIL-2 (500 µg/
ml) were mixed at 1:10 or indicated molecular ratio and
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incubated for 30 min at RT. The complex was diluted in PBS
for injection volume (200 µl/injection).
CTV labeling and adoptive cell transfer of lymphocytes
Lymph node cells from Thy1.1+ Foxp3-eGFP+ mice were
labeled with CellTrace Violet (CTV, Thermofisher) according
to the protocol from the manufacturer and then 107 cells were
intravenously injected on day 0. hIL-2/anti hIL-2 complex was
injected daily from day 0 to 3 and then the proliferation of
donor cells were measured on day 5.
CTLL2 cell proliferation assay
CTLL2 cell line was purchased from ATCC and cultured in
the presence of indicated serum for 2 days. The proliferation
of CTLL2 cells was analyzed with CellTiter 96® Non-
Radioactive Cell Proliferation Assay (MTT, Promega) accord-
ing to the manufacturer’s protocol.
Affinity measurement for anti-hIL-2 mAbs
Nine hundred RU (Rmax = 90) of MAB602, 5344 or TCB2
(produced from serum-free media) were immobilized on CM5
chip (GE healthcare) by amine reaction. A twofold serial
dilution of hIL-2 starting at 100 nM was pulsed for 3 min at
10 µl/min and then dissociation of hIL-2 was chased for 10 min.
The surface plasmon resonance curve was obtained using
Biacore T100 (GE healthcare) or Biacore T200 at Postech
(Pohang, Korea) or Unist (Ulsan, Korea), respectively.
CDR region sequencing of anti-hIL-2 mAbs
CDR region of antibody heavy chain and light chain sequencing
was performed as previously described.14 In brief, RNA was
isolated from 5 × 106 hybridoma cell line using TRIzol
(Thermofisher) according to the protocol from the manufac-
turer. cDNA was synthesized using QuantiTect Reverse
Transcription Kit (Qiagen) according to the protocol from
manufacturer. PCRs for the variable region of light chain and
heavy chain were performed as previously described.14 The PCR
products were cloned into TA vector (Thermofisher) and then
DNA sequencing was performed at Cosmogenetech.
Production of recombinant human-chimeric and
humanized TCB2
Antibody humanization was performed in GenScript (USA)
and cloned into a human IgG1 backbone. Humanized TCB2
(hTCB2) were expressed using ExpiCHO Expression System
(Thermofisher) according to the protocol from manufacturer.
Purification of antibody was performed with protein G resin
with purity more than 95%.
Tumor models
B16F10, MC38, and CT26 cell lines were purchased from
ATCC. For all tumor experiments, we injected reagents into
mice with a measurable tumor mass. B16F10 cells (1 × 106)
were subcutaneously injected into B6 mice on day 0 and PBS,
hIL-2 alone (1.5 µg), hIL-2/TCB1 (0.8 µg/8 µg) or hIL-2/TCB2
(0.8 µg/8 µg) complex were daily injected intraperitoneally
from day 4 to 7. Trp2180-188 [SVYDFFVWL] (100 µg,
Peptron) and poly:IC (100 µg, Invivogen) were injected
on day 3 and 10 and hIL-2/TCB2c daily injected from day 4
to 7 and day 11 to 14.15 The systemic tumor model was
generated by intravenously injecting B16F10 cells (3 × 105) as
previously described.8 For the anti-CTLA4 and hIL-2/TCB2c
co-treatment experiment, CT26 cells (5 × 105) were subcuta-
neously injected into BALB/c mice and injected with anti-
mouse CTLA4 (UC10-4F10-11, BioXcell, 100 µg, on day 7, 9
and 11) and/or hIL-2/TCB2 complex (0.8 µg/8 µg on day 8, 9,
10 and 11) after tumor inoculation. For testing synergistic anti-
tumor response of anti-PD-1 and hIL-2/TCB2c, MC38 cells
(5 × 105) were subcutaneously injected into B6 mice, which
were injected with anti-mouse PD-1 (29F.1A12, BioXcell,
100 µg, on day 7, 10 and 13) and/or hIL-2/TCB2 complex
(0.8 µg/8 µg, day 8, 9, 10, 11) after tumor inoculation. To test
the anti-tumor memory response, MC38 cells (5 × 105) were
injected to tumor cured or naïve B6 mice. Tumor-bearing mice
were sacrificed when the tumor size reaches 800 mm3.
Ethics statement
This research was approved by the Institutional Animal Care
and Use Committees (IACUC) of the Pohang University of
Science and Technology (2013–01–0012). Mice care and
experimental procedures were performed in accordance with
all institutional guidelines for the ethical use of non-human
animals in research and protocols from IACUC of the Pohang
University of Science and Technology.
Results
Development of new anti-hIL-2 antibodies
To develop a new anti-hIL-2 antibody that can selectively
stimulate CD8 T or NK cells when complexed with hIL-2
in vivo, we immunized BALB/c mice with hIL-2 and screened
antibodies under two criteria: first, it binds to human, but not
mouse IL-2; second, its binding to hIL-2 is blocked by
MAB602, but not by 5344. Although the binding epitope of
MAB602 and 5344 have not yet been analyzed, we assumed
that the former and the latter block CD25 and CD122/CD132
binding sites, respectively, based on a structural analysis of
their respective functional counterparts of mouse antibodies,
S4B6 and JES6-1.16 After the vigorous screening, we generated
three anti-hIL-2 antibody clones named TCB1, TCB2, and
TCB3. These clones were only reactive to hIL-2, whereas
MAB602 reacted mouse IL-2 (mIL-2) to some extent as pre-
viously shown11 (Figure S1A). In ELISA, when hIL-2 was first
treated with either TCB1-3 or MAB602, the binding of other
antibodies of these could be completely blocked, indicating
that these four antibodies have significant overlap in their
epitopes and cause steric hindrance (Figure S1B and C). We
sequenced the CDR regions of TCB1–3 and compared them
with those of Nara1, which has been previously known to
block the CD25 binding site of hIL-2.11 Interestingly, the
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CDRs of TCB1 and TCB3 had about 80% sequence homology
with those of Nara1, suggesting that they might share
a common binding epitope (Table 1). However, TCB2 had
unique CDRs, and their sequence similarities with Nara1 were
34% in average. Collectively, these results show that TCB2 is
a new anti-hIL-2 antibody that is different from Nara1 and
shares a common binding epitope with MAB602.
hIL-2/TCB2c selectively stimulates CD8 T and NK cells
while relatively disfavoring treg activation
To test the in vivo activity of hIL-2/TCBc in mouse, we trans-
ferred CellTrace Violet (CTV)-labeled donor lymph node (LN)
cells isolated from Thy1.1 Foxp3-eGFP mice to a congenic host
and injected hIL-2/TCBc. As shown in Figure 1a, 1.5 μg of hIL-2
alone was not sufficient to drive CD8 T cell proliferation.
However, 0.8 μg of hIL-2 complexed with 8 μg of TCBs, espe-
cially hIL-2/TCB2c, induced robust donor T cell activation in
terms of CTV dilution, CD44 upregulation, and granzyme
B secretion (Figure 1a,b). Herein, we chose TCB2 for further
development and analyzed its effects on the host immune cells
(Figure 2). hIL-2/TCB2c induced vigorous proliferation of CD8
T (60-folds) and NK (18-folds) cells while relatively disfavoring
Treg expansion (5-folds) (Figure 2a,b). After four consecutive
injections of hIL-2/TCB2c, the numerical ratio of memory phe-
notype (MP) CD8 T cells or NK cells to Tregs increased eight-
and fivefold, respectively. NK cells are classified into four main
developmental stages based on the expression of CD11b and
CD27; most immature CD11b–CD27 – cells matured sequen-
tially into CD11b–CD27+, CD11b+CD27+, and CD11b+CD27 –
cells.17,18 Upon hIL-2/TCB2c injection, all four subsets of NK
cells expanded with upregulation of activation marker CD69,19
particularly in CD11b+ populations, which had high cytotoxic
activity20 (Figure 2c,d). The effect of T cell proliferation after
hIL-2/TCB2c injection lasted for more than 2 weeks after injec-
tion and the increased memory cell proportion persisted for
more than a month (Figure S2). Therefore, hIL-2/TCB2c selec-
tively expanded and activated CD8 T and NK cells for extended
periods.
hIL-2/TCB2c provides prolonged IL-2 receptor stimulation
to MP CD8 T cells, which express the highest level of
heterodimeric IL-2 receptor
As phosphorylation of STAT5 protein is a downstream event of
IL-2 receptor engagement,21 we measured its expression in
T cells and used it as a readout of signal intensity of IL-2. hIL-
2 complexed with 5344, MAB602, or TCB2 were intravenously
(IV) injected and pSTAT5 upregulation on circulating CD8 T,
NK and Tregs were analyzed 20 or 180 min later (Figure 3a,b).
As expected, hIL-2 alone, hIL-2/MAB602c, and hIL-2/TCB2c
uniformly upregulated pSTAT5 on CD8 T cells and Tregs 20
min after injection (Figure 3a). Due to its short half-life, hIL-2
alone resulted in relatively short-lived upregulation of pSTAT5
on CD8 T cells that disappeared after 180 min. However, its
effect lasted beyond 180 min after injection when complexed
with its antibodies. Interestingly, pSTAT5 was upregulated in
NK cells only when IL-2 was injected in complex form 180 min
after injection, but not at 20 min later (Figure 3a,b). We found
the pSTAT5 level was higher in T cells injected with hIL-2/
TCB2c than with hIL-2/MAB602c (Figure 3a,b), indicating that
the former has a longer in vivo half-life. When we analyzed the
in vitro survival of the CTLL2 cell line, which is dependent on IL-
2 for survival, it was estimated that hIL-2/TCB2c had about a 48-
h half-life in the serum (Figure S3). This is significantly longer
than that of hIL-2/MAB602c, which has about a 36-h half-life.
Clone 5344, like JES6-1, worked only on Tregs as expected
(Figure 3a,b).8 On Tregs, all complexes worked equally well at
the 20 and 180-min time points. This could be due to the stability
of the heterotrimeric IL-2 receptor complex on Tregs. As
a result, the pSTAT5 mean fluorescent intensity (MFI) ratio of
CD8/Treg was the highest with hIL-2/TCB2c (Figure 3a,b,
right). To explain why IL-2 works best on MP CD8 T cells
when antibody interferes with CD25 binding, we analyzed the
expression patterns of IL-2 receptor subunits on T cells
(Figure 3c,d). Only Tregs expressed CD25, but they had an
intermediate level of CD122 expression; on the other hand,
MP CD8 T cells expressed the highest levels of CD122
(Figure 3c). Although CD132 was slightly higher in Tregs, this
result explains how MP CD8 T cells outcompete Tregs and CD4
T cells when CD25 is not able to engage IL-2.
hIL-2/TCB2c has better in vivo efficacy than hIL-2/
MAB602c
The binding epitope on IL-2 for the anti-IL-2 mAb seems to be
amajor factor determining the functional heterogeneity of the IL-2
cytokine-antibody complex.2,16 However, the previous results sug-
gested that the affinity of antibodies could also influence the
quality of T cell subset stimulation. To address this, we measured
the affinity of anti-hIL-2 mAbs for hIL-2 using surface plasmon
resonance (Figure S4). The hIL-2 binding curve was slightly
(16.7%) higher with TCB2 than with MAB602, and the dissocia-
tion rate was much slower (44.1%) for TCB2 than for MAB602.
Overall, the affinity of MAB602 for hIL-2 was expected to be 38%
of that of TCB2. The binding pattern of 5344 to hIL-2was different
Table 1. TCB2 has unique CDR sequences.
Amino acid sequence
Sequence homology
with Nara1 (%)
CDRs Nara 1 TCB1 TCB2 TCB3 TCB1 TCB2 TCB3
κ1 KASQSVDYDGDSYMN KASQSVDYDGDSYMN ITSTDID DDMN KASQSVDYDGDSYMN 100 27 100
κ2 AASNLES AASNPES EGNTLRP AASNLES 83 14 100
κ3 QQSNEDPYT QQSNEDPWT LQSDNLPYT QQSNEDPWT 89 56 89
H1 NYLIE NYLIE TYWIQ NYLIE 100 40 100
H2 VINPGSGGTNYNEKFKG VINPGSGGTNYNEKFKG AIYPGDGDTRYIQNFKG VINPGSGGSNYNEKFKG 100 53 94
H3 WRGDGYYAYFDV DYGLHRLDY SLATRGFYAMDY WDFGYAMDY 8 17 17
Ave 80 34 83
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from that of MAB602 and TCB2, suggesting that it might have
a different mode of interaction with hIL-2. Next, we tested if the
prolonged in vivo half-life (Figure 3) and in vitro affinity (Figure
S4) of hIL-2/TCB2c compared to hIL-2/MAB602c can drive better
immune cell response. Two-fold serial dilutions of hIL-2/TCB2c
or hIL-2/MAB602c were intraperitoneally injected into mice for
four consecutive days and T cell proliferation was measured 48
h after the last injection (Figure 4). The number ofMPCD8T cells
was higher in the hIL-2/TCB2c-injected group than in the hIL-2/
MAB602c-injected group, while the number of Tregs was not
significantly different between them (Figure 4). As a result, 0.8/8
μg injection of hIL-2/TCB2c andhIL-2/MAB602c induced average
7.7 and 3.7-fold increases inMPCD8/Treg numbers ratio, respec-
tively (Figure 4b, right). Furthermore, hIL-2/TCB2c induced
stronger NK expansion (Figure S5A, right), as well as more gran-
zyme B (Figure S5B) and IFNγ-producing (Figure S5C) CD8
T cells in the spleen. Collectively, we showed that hIL-2/TCB2c
has a higher affinity and longer half-life than hIL-2/MAB602c, and
it induced a more robust CD8 T and NK cell response.
hIL-2/TCB2c enhances anti-tumor immunity and
synergizes with the peptide-based tumor vaccine and
checkpoint inhibitor
To demonstrate the potential clinical utility of the TCB2 mAb
against human cancer patients, we established a malignant mel-
anoma model using B6 mice inoculated with B16F10 cells sub-
cutaneously. Then, the mice were injected with PBS, hIL-2 alone,
a
b
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40
20
0
200
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Figure 1. Generation of anti-human IL-2 antibodies that stimulate CD8 T cells as a cytokine-antibody complex.
B6 mice were injected with CellTrace violet (CTV) labeled lymph node cells from Thy1.1+ Foxp3-eGFP+ mice on day 0, followed by daily injections with hIL-2 (1.5 µg)
or indicated antibody complexes (0.8 µg/8 µg) from day 0 to 3. The proliferation, activation and granzyme B expression of CD8 T cells in the spleen were analyzed
on day 5 by flow cytometry. (a) Representative histograms and dot plots are shown. Numbers indicate the frequency of cells in adjacent gates or regions. (b) Graphs
show the statistical analysis of proliferation, memory phenotype (CD44hi) acquisition and granzyme B secretion of splenic CD8 T cells. Each dot represents individual
mouse and horizontal bars indicate mean values. Error bars indicate standard deviation (SD). *p <.05; **p <.01; ***p <.001 (one-way ANOVA). hIL-2/TCB2c, human IL-
2/TCB2 complex. A representative result is shown from three independent experiments using 3-4 mice per group.
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hIL-2/TCB1c or hIL-2/TCB2c from day 4 to 7, and tumor
progression was monitored for the next 7 days (Figure 5a).
As expected, tumor growth was most strongly inhibited by
treatment with hIL-2/TCB2c, followed by with hIL-2/TCB1
complex and with hIL-2 alone. This result is well correlated
with the observed magnitude of CD8 T cell expansion
(Figure 1). Next, we tested the effect of TCB2 in a systemic
tumor model using B6 mice that were IV injected with B16F10
melanoma cells (Figure 5b). The mice were injected daily with
hIL-2/TCB2c fromday 4 to 7 and then the number of pulmonary
tumor nodules was measured on day 18. Similar to the solid
B16F10 model, we observed hIL-2/TCB2c most significantly
suppressed the growth of pulmonary tumor nodules.
We further tested if hIL-2/TCB2c has synergistic effects
with other anti-tumor therapies, such as T cell stimulation
with tumor neo-antigen15,22 and checkpoint inhibitors 23,24 B6
mice were subcutaneously injected with B16F10 melanoma
cells and injected with PBS or Poly I:C plus TRP2 peptide15
as indicated (Figure 5c). TRP2 peptide or hIL-2/TCB2c sig-
nificantly delayed the growth of B16F10 tumor; however,
a
b
c d
Figure 2. hIL-2/TCB2c selectively stimulates CD8 T and NK cells while relatively disfavoring Treg activation.
B6 mice were daily injected with PBS or hIL-2/TCB2c (0.8 µg/8 µg) from day 0 to 3 and splenocytes were analyzed on day 5. (a and c) Single-cell suspension of
splenocytes were stained with indicated markers and analyzed by flow cytometry. Representative dot plots are shown and numbers indicate the frequency of cells in
adjacent gates or each quadrant. (b and d) Graphs shows numbers or frequencies of indicated populations with statistical analysis (N = 3 ~ 5). Each dot represents
individual mouse and horizontal bars indicate mean values. Error bars indicate standard deviation (SD). *p <.05; **p <.01; ***p <.001 (unpaired t-test). hIL-2/TCB2c,
human IL-2/TCB2 complex. A representative result is shown from four (a and b) and 2 (c and d) independent experiments.
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when TRP2 peptide was used in combination with hIL-2/
TCB2c, the anti-tumor effect was further enhanced. Next,
we tested the synergistic anti-tumor effect of anti-PD1 with
hIL-2/TCB2c using a suboptimal dose of anti-PD-1 that could
not elicit an anti-tumor response, thus mimicking the clinical
condition wherein anti-PD1 therapy is not fully effective
b
a
c
d
Figure 3. hIL-2/TCB2c provides prolonged IL-2 receptor stimulation to MP CD8 T cells, expressing the highest level of heterodimeric IL-2 receptor.
(a and b) B6 mice were injected with PBS, hIL-2 (1 µg) or hIL-2/TCB2c (1 µg/10 µg) once and pSTAT5 in lymphocytes were analyzed after 20 and 180 min. Representative
histograms show pSTAT5 expression in CD8 T, NK and regulatory T cells (a). Statistical analysis of pSTAT5 MFIs of indicated cell types and their ratios are shown (N = 3) (b). (c and
d) Representative histograms show surface expression of IL-2 receptor subunits in indicated cell types (c) and statistical analysis of MFIs of IL-2 receptor subunits are shown (N
= 3) (d). Each dot represents individual mouse and horizontal bars indicate mean values. Error bars indicate standard deviation (SD). MFI, mean fluorescence intensity; *p < .05;
**p < .005; ***p < .001(one-way ANOVA); hIL-2/TCB2c, human IL-2/TCB2 complex; NS, not significant. Representative result is shown from three independent experiments.
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(Figure 5d). Consistent with the result from B16F10 tumors,
hIL-2/TCB2c alone could significantly delay MC38 tumor
growth and eradicated tumors in 3 out of 8 mice (37%)
(Figure 5d). Remarkably, when a suboptimal dose of anti-
PD1 antibody was combined with hIL-2/TCB2c, it completely
rejected tumors in all 7 mice (Figure 5d). We also tested if
tumor-free mice would become resistant to secondary tumor
challenge. At day 25, MC38 tumor cells were re-inoculated in
tumor-free mice from the hIL-2/TCB2c (N = 3) or hIL-2/
TCB2c plus anti-PD1 mAb-treated (N = 7) groups
(Figure 5d). Surprisingly, tumors did not grow again in any
of these mice that rejected the first tumor. The synergistic
anti-tumor response was also observed in a CT26 colon tumor
model treated with an anti-CTLA4 antibody (Figure S6).
Collectively, these results demonstrate that TCB2 is a potent
anti-hIL-2 mAb that has a therapeutic potential for cancer
immunotherapy when used as hIL-2/TCB2c alone, or in com-
bination with checkpoint blockers or a tumor vaccine.
Humanized form of TCB2 provides effective anti-tumor
immunity
For the therapeutic application of TCB2 in humans, we generated
various forms of humanized TCB2 (hTCB2) and selected a clone
that has about 70% the affinity of that of a murine one (Figure 6a
and Table S1). We compared the efficacy of T cell stimulation of
TCB2 in B6 mice that were injected with either hIL-2/TCB2c or
hIL-2/hTCB2c (Figure 6b) and found the expansion of CD8 T,
NK, and Treg cells were comparable (Figure 6b). Finally, to con-
firm that the anti-tumor response is preserved in hTCB2, B6 mice
were subcutaneously inoculatedwithMC38 cells and injectedwith
anti-PD1 in combination with either hIL-2/hTCB2c or hIL-2/
b
a
Figure 4. hIL-2/TCB2c has better in vivo efficacy than hIL-2/MAB602c.
Indicated doses of hIL-2/MAB602c or hIL-2/TCB2c were daily injected into B6 mice from day 0 to 3 and splenic T cell activation was analyzed on day 5 by flow
cytometry. (a) Representative dot plots show frequencies of CD44hi cells in total CD8 T cells (upper panels) and Tregs in total CD4 T cells (lower panels). Numbers
indicate the frequency of cells in adjacent gates. (b) Graphs show statistical analysis of absolute numbers of memory phenotype (MP) CD8 T cells (red) and Tregs
(blue) and their numerical ratios in the spleen (right). Pooled results from two independent experiments are shown. Each dot represents individual mouse and
horizontal bars indicate mean values. Error bars indicate standard deviation (SD); *p < .05; **p < .01; ***p < .001 (one-way ANOVA); hIL-2/MAB602c, human IL-2/
MAB602 complex; hIL-2/TCB2c, human IL-2/TCB2 complex. A representative result is shown from two independent experiments using three mice per group.
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TCB2c (Figure 6c). In this experiment, themicewere injectedwith
an optimal dose of anti-PD1 (200 µg/injection) to compare the full
efficacy of tumor growth inhibition (Figure 6c). As expected,
tumor growth was significantly inhibited by both anti-PD1 anti-
body alone and hIL-2/hTCB2 complex alone, and the rejection
rate was 25% and 40%, respectively. Remarkably, injection with
anti-PD1 in combination with either hIL-2/TCB2c or IL-2/
hTCB2c resulted in complete regression of tumors by 100% (7
out of 7) and 90% (8 out of 9), respectively, by day 25 after tumor
graft (Figure 6c). These results indicate that hTCB2 has compar-
able in vivo efficacy with the murine form of TCB2.
Discussion
In this report, we showed that hIL-2/TCB2c preferentially stimu-
lates CD8 T and NK cells, while relatively disfavoring Treg expan-
sion. Although we are still analyzing the molecular structure of
hIL-2 and TCB2 complex, these functional properties are likely
due to the blocking of the CD25 binding motif of hIL-2 by TCB2.
Tregs expressed an intermediate level of heterodimeric IL-2Rβγ
and, therefore, in the absence ofCD25 binding ability, IL-2 favored
MPCD8T cells, which express the highest level of IL-2Rβγ (Figure
3c). When the mice were injected with hIL-2 alone or hIL-2
d
ba c
Figure 5. hIL-2/TCB2c enhances anti-tumor immunity and synergizes with peptide-based tumor vaccine and a checkpoint inhibitor.
(a) B6 mice were subcutaneously inoculated with B16F10 melanoma cells on day 0 and daily injected with hIL-2/TCB1c (0.8 µg/8 µg) or hIL-2/TCB2c (0.8 µg/8 µg)
from days 4 to 7. Tumor growth was monitored until day 14 (N = 8 ~ 10). ***p < .001 (Two-way ANOVA for day 12, unpaired t test for day 14). (b) B6 mice were
intravenously injected with B16F10 melanoma cells on day 0 and daily injected with hIL-2 (0.8 µg) or hIL-2/TCB2c (0.8 µg/8 µg) from days 4 to 7. Pictures show
representative lung specimen (top) and a graph shows a statistical analysis of the number of pulmonary tumor nodules on day 18 (N = 3 ~ 4, bottom). Each dot
represents individual mouse and horizontal bars indicate mean values. Error bars indicate standard deviation (SD). ***p < .001 (One-way ANOVA); NS, not significant.
(c) B6 mice were subcutaneously inoculated with B16F10 melanoma cells on day 0 and injected with either PBS, Trp2 peptide (100 µg) plus Poly:IC (100 µg), hIL-2/
TCB2c (0.8 µg/8 µg) or Trp2 peptide (100 µg) plus Poly:IC (100 µg) with hIL-2/TCB2c (0.8 µg/8 µg) on indicated days. Graph shows tumor progression measured
thereafter [N = 6 (PBS), N = 8 (peptide+Poly:IC), N = 7 (hIL-2/TCB2c), N = 10 (peptide+Poly:IC+hIL-2/TCB2c)]. (D) B6 mice were subcutaneously inoculated with MC38
colon cancer cells on day 0 and injected with PBS or suboptimal dose of anti-PD1 (100 µg) and/or hIL-2/TCB2c (0.8/8 µg) as indicated (N = 6 ~ 8). At day 25, tumor-
free mice (N = 3 for hIL-2/TCB2 and N = 7 for anti-PD1 + hIL-2/TCB2) were inoculated again with MC38 cells and tumor progression was monitored until day 42.
Graphs shows tumor volume (left) and percentage of tumor-free mice (right). Error bars indicate standard error of mean (SEM). *p < .05; ***p < .001 (One-way (b) and
Two-way (a, c, and d) ANOVA). hIL-2/TCB2c, human IL-2/TCB2 complex. Representative result is shown from three independent experiments.
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ac
b
Figure 6. Humanized form of TCB2 provides effective anti-tumor immunity.
(a) Figure shows the results of surface plasmon resonance for binding of fully humanized TCB2 (hTCB2) to hIL-2. (b) B6 mice were daily injected with PBS, hIL-2/
TCB2c (0.8 µg/8 µg) or hIL-2/hTCB2c (0.8 µg/8 µg) from day 0 to 3 and splenic T cells were FACS analyzed on day 5. Graphs show numbers of indicated cells and
ratios. Each dot represents individual mouse and horizontal bars indicate mean values (N = 2 ~ 3). Error bars indicate standard deviation (SD). (c) B6 mice were
subcutaneously inoculated with MC38 cells on day 0 and injected with PBS, anti-PD1 (200 µg/injection) and/or hIL-2/TCB2c or hIL-2/hTCB2c (0.8/8 µg, N = 7 ~ 9)
as indicated. Graphs shows tumor volume (left) and percentage of tumor-free mice (right). Error bars indicate standard error of mean (SEM). *p < .05; **p < .01
(Two-way ANOVA (day 19/22) and unpaired t test (day 25); NS, not significant. hIL-2/TCB2c, human IL-2/TCB2 complex. Shown are the result of two (a and b) or
three (c) independent experiments.
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antibody complexes, pSTAT5 expressions in CD8 T cells were
proportional to their proliferation capacity, suggesting pSTAT5
faithfully report signaling intensity of IL-2Rβγ complex (Figure 3a,
b). Interestingly, Tregs had a similar pattern of pSTAT5 expression
regardless of the hIL-2 formulation andNK cells showed a delayed
response with pSTAT5 upregulation. One possible explanation is
that a small amount of IL-2 released from the complex and
captured by CD25, which is constitutive on Tregs and inducible
on NK cells with cytokine stimulation such as IL-12 and IL-18.25
This might be enough for the phosphorylation of STAT5 in Tregs,
but not for their proliferation.However, this does not explain overt
NK cell activation and proliferation by hIL-2/TCB2c after repeti-
tive injections (Figure 2). There may be more complex cytokine
storms after administration of IL-2 and further investigations are
required to understand the heterogeneous response of each cell
type.
There are several recently developed IL-2-mediated anti-
tumor drugs, such as neoleukin-2/1517 anti-hIL-2 (Nara1),11
IL-2 superkine,26 CEA-IL-2v27, and NKTR-214.28,29 IL-2
superkine is a selected mutant that had increased affinity for
IL-2Rβ without CD25, and neoleukin-2/15 is designed mimics
of IL-2 that has decreased affinity to CD25, thereby working
better on CD8 T cells than Tregs. Similarly, CEA-IL-2v is an
anti-CEA antibody linked with a variant of hIL-2 that has
a mutated CD25 binding site, thereby recruits CD8 T cells to
tumor cells that express CEA antigen. However, these muta-
tion-based approaches could potentially render the modified
IL-2 immunogenic and/or susceptible to proteolytic enzymes
that degrade artificially introduced amino acid sequences.
NKTR-214 is a prodrug of hIL-2 that is PEGylated on the
CD25 binding site, in which six PEG residues are slowly
released to make an active and stable form of hIL-2. As PEG
molecules block the CD25 binding motif, it preferentially acti-
vates heterodimeric IL-2 receptors over heterotrimeric
complexes.28–30 These properties rendered hIL-2 to have
increased serum half-life without overt Treg activation and
toxic side effects. This mode of action, however, could possibly
induce continuous IL-2 signaling on T cells with low levels of
stimulation, as most active forms are not stable and most stable
forms are not active. In contrast, hIL-2/TCB2c does not require
an activation step and is stable. We also noticed that four
consecutive high-dose injections of hIL-2/TCB2 (0.8 µg/8 µg)
had an equal or better anti-tumor effects compared with seven
consecutive low-dose injections (0.6 µg/6 µg), although the
total amount of IL-2 was higher in the latter (Figure S7). This
finding may suggest that there is a certain threshold for IL-2
signaling required for optimal T cell activation. We estimated
from the literature that, for the mouse in vivo usage,
0.160–0.320 mg/kg of TCB2 was comparable with 2 mg/kg of
NKTR214 and 4 mg/kg of IL-2 superkine. As a result, we
showed that hIL-2/TCB2c could inhibit tumor growth in
mouse models of malignant melanoma (B16F10) and colon
cancer (MC38 and CT26) (Figure 5 and S6). Also, hIL-2/
TCB2c showed synergy with checkpoint blockers such as anti-
PD1 and anti-CTLA4 similar to previous reports.28,31,32
We showed that TCB1, TCB3, and Nara1 share similar
CDR sequences, but TCB2 has a unique one. It was quite
surprising that TCB1, TCB3 and Nara1, which were devel-
oped in different sets of experiments, had high homology in
their CDR sequences. We speculate that CD25 binding epi-
tope on hIL-2 is very restricted, and there is not many chances
for having different CDRs for efficient binding. IL-2 epitopes
of TCB antibodies overlap with each other, and it is possible
that TCB2 directly binds to the CD25 recognition motif,
rather than binding to its adjacent area and provide steric
hindrance as shown in Nara1.11 To address this issue, we are
analyzing the detailed structure of the hIL-2/TCB2c by X-ray
crystallography, which will reveal the precise mode of binding
by TCB2 to hIL-2.
For human clinical application, we generated a humanized
form of TCB2 and confirmed that it has similar anti-tumor
effects and is ready for clinical trials (Figure 6). To minimize
Treg activation by IL-2 released from the complex, as well as
make it easier and cheaper for mass production, we are
currently generating a single chain complex wherein hIL-2
and TCB2 are connected by a linker sequence.
When the anti-IL-2 antibody interferes CD122 binding, it
can be used to expand Tregs as seen in clone 5344 (anti-
human IL-2) and JES6-1 (anti-mouse IL-2) with which CD8
T cells are minimally affected. Upon structural analysis, JES6-
1 was observed to block IL-2Rβ (CD122) binding, but CD25
could peel off the antibody and allow IL-2 to bind hetero-
trimeric complexes.16 A newly generated anti-hIL-2 antibody
F5111 had a similar mode of action and could treat autoim-
mune disorders, such as type I diabetes in NOD mice, as well
as experimental allergic encephalitis and xenogeneic graft-
versus-host diseases.33 IL-2/F5111 complex blocked the
CD122 binding site with relatively weak affinity and CD25/
IL-2 binding released F5111, allowing them to form IL-2/IL-
2Rαβγ tetrameric complex. Therefore, Treg-expanding clones
might need to have a modest binding affinity to IL-2 to make
their release easier.
The recent success of checkpoint blockers revolutionized
tumor immunotherapy. However, their response rate is about
20–30%, and there is a critical need to combine other ther-
apeutic modalities such as conventional chemo-radiotherapy,
intestinal microbiome or immunological adjuvants to enhance
its efficacy.34,35 Of them, IL-2 is one of the best candidates to
expand immune cells in the body, and we showed that
a cytokine-antibody complex-based approach could maximize
its efficacy while minimizing its adverse effects.
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